Vardenafil: Structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5)

Neurochemistry International

Volumn 45, Issue 6, 2004, Pages 859-863

  Corbin, Jackie D ^a   Beasley, Alfreda ^a   Blount, Mitsi A ^a   Francis, Sharron H ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cGMP; Erectile dysfunction; Phosphodiesterase 5; Sildenafil; Vardenafil

Indexed keywords

CYCLIC GMP; METHYLSILDENAFIL; NORVARDENAFIL; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PIPERAZINE; PURINE DERIVATIVE; SILDENAFIL; TADALAFIL; UNCLASSIFIED DRUG; VARDENAFIL;

CATALYST; CHEMICAL STRUCTURE; CONFERENCE PAPER; DRUG BINDING; ERECTILE DYSFUNCTION; HUMAN; IC 50; PRIORITY JOURNAL;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ANIMALS; HUMANS; IMIDAZOLES; MALE; METHYLATION; MODELS, MOLECULAR; PENILE ERECTION; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONES; TRIAZINES;

EID: 4243194585     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2004.03.016     Document Type: Conference Paper

References (14)

1. 3H ]sildenafil binding to phosphodiesterase-5 is specific Mol. Pharmacol. 63:2003;1364-1372
2. Corbin J.D., Francis S.H. Cyclic GMP phosphodiesterase-5: target of sildenafil. J. Biol. Chem. 274:1999;13729-13732
3. Corbin J.D., Francis S.H. Pharmacology of phosphodiesterase-5 inhibitors. Int. J. Clin. Pract. 56:2002;453-459
4. Corbin J.D., Turko I.V., Beasley A., Francis S.H. Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities. Eur. J. Biochem. 267:2000;2760-2767
5. Gopal V.K., Francis S.H., Corbin J.D. Allosteric sites of phosphodiesterase-5 (PDE5). A potential role in negative feedback regulation of cGMP signaling in corpus cavernosum. Eur. J. Biochem. 268:2001;3304-3312
6. Jeremy J.Y., Ballard S.A., Naylor A.M., Miller M.A., Angelini G.D. Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro. Br. J. Urol. 79:1997;958-963
7. Klotz T., Sachse R., Heidrich A., Jockenhovel F., Rohde G., Wensing G., Horstmann R., Engelmann R. Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. World J. Urol. 19:2001;32-39
8. Lue T.F. Erectile dysfunction. N. Engl. J. Med. 342:2000;1802-1813
9. Montorsi F., Salonia A., Deho F., Cestari A., Guazzoni G., Rigatti P., Stief C. Pharmacological management of erectile dysfunction. BJU Int. 91:2003;446-454
10. Padma-Nathan H., McMurray J.G., Pullman W.E., Whitaker J.S., Saoud J.B., Ferguson K.M., Rosen R.C. On-demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction. Int. J. Impot. Res. 13:2001;2-9
11. Robison, G.A., Butcher, R.W., Sutherland, E.W., 1971. Cyclic AMP. Academic Press, New York.
12. Rotella D.P. Phosphodiesterase 5 inhibitors: current status and potential applications. Nat. Rev. Drug Discov. 1:2002;674-682
13. Saenz de Tejada I., Angulo J., Cuevas P., Fernandez A., Moncada I., Allona A., Lledo E., Korschen H.G., Niewohner U., Haning H., et al. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int. J. Impot. Res. 13:2001;282-290
14. Sung B.J., Yeon Hwang K., Ho Jeon Y., Lee J.I., Heo Y.S., Hwan Kim J., Moon J., Min Yoon J., Hyun Y.L., Kim E., et al. Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules. Nature. 425:2003;98-102